Annals of oncology : official journal of the European Society for Medical Oncology
-
Multicenter Study
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
NTRK1, NTRK2 and NTRK3 gene fusions (NTRK gene fusions) occur in a range of adult cancers. Larotrectinib is a potent and highly selective ATP-competitive inhibitor of TRK kinases and has demonstrated activity in patients with tumours harbouring NTRK gene fusions. ⋯ NCT02122913.